Clinically relevant doses and blood levels produce experimental cyclosporine nephrotoxicity when combined with nitric oxide inhibition

Transplantation

Volumn 61, Issue 10, 1996, Pages 1506-1512

  Gardner, Michael P ^a   Houghton, Donald C ^b   Andoh, Takeshi F ^a   Lindsley, Jessie ^a   Bennett, William M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE METHYL ESTER; CYCLOSPORIN; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; GLOMERULUS FILTRATION RATE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY INJURY; MALE; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ARGININE; BODY WEIGHT; CYCLOSPORINE; DIET, SODIUM-RESTRICTED; ENZYME INHIBITORS; HEMODYNAMIC PROCESSES; KIDNEY CORTEX; KIDNEY DISEASES; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0029929943     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199605270-00017     Document Type: Article

References (54)

1. Myers BD, Newton L, Boshkos C, et al. Chronic injury of human renal microvessels with low dose cyclosporine therapy. Transplantation 1988; 46: 694.
2. Rego A, Vargas R, Seedabarum C, Kuwaha M, Foegh M, Ramwell P. Systemic vascular effects of cyclosporine A treatment in normotensive rats. J Pharmacol Exp Ther 1992; 259: 905.
3. Bennett WM, Norman DJ. Action and toxicity of cyclosporine. Annu Rev Med 1986; 37: 215.
4. Dieterle A, Gratwohl A, Nizze H, et al. Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients. Transplantation 1990; 49: 1093.
5. Burdmann EA, Andoh T, Nast C, et al. Prevention of experimental cyclosporine-induced interstitial fibrosis by losartan and enalapril. Am J Physiol (in press).
6. Siegal H, Ryffel B. Effect of cyclosporin on renin-angiotensin-aldosterone system. Lancet 1982; 2: 1274.
7. Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I, Hoover RL. Role of endothelin in cyclosporine-induced glomerular damage. Kidney Int 1990; 37: 1487.
8. Voss BL, Hamilton KK, Samara ENS, McKee PA. Cyclosporine suppression of endothelial prostacyclin generation: a possible mechanism for nephrotoxicity. Transplantation 1988; 45: 793.
9. Pavao dos Santos OF, Boim MA, Bregman R, et al. Effect of platelet-activating factor antagonist on cyclosporine nephrotoxicity. Transplantation 1989; 47: 592.
10. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelial-derived relaxing factor. Nature 1987; 327: 524.
11. Gerkins JF. Cyclosporine treatment of normal rats produces a rise in blood pressure and decreased renal vascular responses to nerve stimulation, vasoconstrictors, and endothelial-dependent dilators. J Pharmacol Exp Ther 1989; 250: 1105.
12. Gallego M, Garcia Villalon AL, Lopez Farre AJ, et al. Mechanisms of the endothelial toxicity of cyclosporine A: role of nitric oxide, cGMP, and Ca2+. Circ Res 1994; 74: 477.
13. Ribeiro MO, Antunes E, deNucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension 1992; 20: 298.
14. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992; 90: 278.
15. G-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol 1991; 261: F1033.
16. De Nicola L, Thomson SC, Wead LM, Brown MR, Gabbai FB. Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest 1993; 92: 1859.
17. Zoja C, Furci L, Ghilardi F, Zinio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial injury. Lab Invest 1986; 55: 455.
18. Dieperink H, Leyssac PP, Starklint H, Kemp E. Long-term cyclosporin nephrotoxicity in the rat: effects on renal function and morphology. Nephrol Dial Transplant 1988; 3: 317.
19. Gillum DM, Truong L, Tasby J, Migliore P, Suki WN. Chronic cyclosporine nephrotoxicity: a rodent model. Transplantation 1988; 46: 285.
20. Rosen S, Greenfeld Z, Brezis M. Chronic cyclosporine-induced nephropathy in the rat: a medullary ray and inner stripe injury. Transplantation 1990; 49: 445.
21. Elzinga LW, Rosen S, Bennett WM. Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine-nephropathy: role of sodium intake. J Am Soc Nephrol 1993; 4: 214.
22. Young BA, Burdmann EA, Johnson RJ, et al. Cyclosporine A induced arteriolopathy in a art model of chronic cyclosporine nephropathy. Kidney Int (in press).
23. Conrad KP, Joffe GM, Kruszyna H, et al. Identification of increased nitric oxide biosynthesis during pregnancy in rats. FASEB 1993; 7: 566.
24. Dihn Xuan AT, Fan TPD, Higenbottam TW, Wallwork J. Cyclosporine in vitro reduces endothelial-dependent relaxation to acetylcholine but does not affect relaxation to nitrovasodilators. Transplant Proc 1990; 22: 1723.
25. Gallego MJ, Lopez Farre A, Riesco A, et al. Blockade of endothelium-dependent responses in conscious rats by cyclosporine A: effect of L-Arg. Am J Physiol 1993; 264: H708.
26. Bobadilla NA, Tapia E, Franco M, et al. Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int 1994; 46: 773.
27. Salazar FJ, Pinilla JM, Lopez F, Romero JC, Quesada T. Renal effects of prolonged synthesis inhibition of endothelial-derived nitric oxide. Hypertension 1993; 20: 113.
28. Pollack DM, Polakowski JS, Divish BJ, Opgenorth TJ. Angiotensin blockade reverses hypertension during the long-term nitric oxide synthase inhibition. Hypertension 1993; 21: 660.
29. Qui C, Engels K, Baylis C. Angiotensin II and alpha 1-adrenergic tone in chronic nitric oxide blockade-induced hypertension. Am J Physiol 1994; 266: R1470.
30. Jover B, Herizi A, Ventre F, Dupont M, Mimran A. Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension 1993; 21: 944.
31. Scholz H, Kurtz A. Involvement of endothelium-derived relaxing factor in the pressure control of renin secretion from isolated perfused kidney. J Clin Invest 1993; 91: 1088.
32. Baxter CR, Duggin GG, Willis NS, Hall BM, Horvath JS, Tiller DJ. Cyclosporin A-induced increases in renin storage and release. Res Commun Chem Pathol Pharmacol 1982; 37: 305.
33. Perico N, Benigni A, Bosco E, et al. Acute cyclosporine A nephrotoxicity in rats: which role for renin-angiotensin system and glomerular prostaglandins? Clin.Nephrol 1986; 25: S83.
34. Duggin GG, Baxter C, Hall BM, Horvath JS, Tiller DJ. Influence of cyclosporine A on intrarenal control of GFR. Clin Nephrol 1986; 25: S43.
35. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590.
36. Bellet M, Cabrol C, Sassano P, Leger P, Corvol P, Menard J. Systematic hypertension after cardiac transplantation: effect of cyclosporine on the renin-angiotensin-aldosterone system. Am J Cardiol 1985; 56: 927.
37. Bantle JP, Boudreau RJ, Ferris TF. Suppression of plasma renin activity by cyclosporine. Am J Med 1987; 83: 59.
38. Gerkins JF, Bhagwandeen SB, Dosen PJ, Smith AJ. The effect of salt intake on cyclosporine-induced impairment on renal in rats. Transplantation 1984; 38: 412.
39. Ingelfinger JR, Pratt RE, Ellison K, Dzau VJ. Sodium regulation of angiotensinogen mRNA expression in rat kidney cortex and medulla. J Clin Invest 1986; 78: 1311.
40. Samani NJ, Swales JD, Brammar WJ. Expression of the renin gene in extra-renal tissues of the rat. Biochem J 1988; 253: 907.
41. Roullet JB, Xue H, McCarron DA, Holcomb S, Bennett WM. Vascular mechanisms of cyclosporin-induced hypertension in the rat. J Clin Invest 1994; 93: 2244.
42. Rego A, Vargas R, Wroblewska B, Foegh ml, Ramwell PW. Attenuation of vascular relaxation and cyclic GMP responses by cyclosporin A. J Pharmacol Exp Ther 1990; 252: 165.
43. Serino F, Grevel J, Napoli KL, Kahan BD, Strobel HW. Generation of oxygen free radicals during the metabolism of cyclosporine A: a cause-effect relationship with metabolism inhibition. Mol Cell Biochem 1993; 122: 101.
44. Maurer G, Lemaire M. Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant Proc 1986; 18(suppl 5): 25.
45. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454.
46. Kumano K, Yoshida K, Iwamura M, et al. The role for reactive oxygen species in cyclosporine A induced nephrotoxicity in rats. Transplant Proc 1989; 21: 941.
47. Walker PD, Lazzaro VA, Duggin GG, Horvat JS, Tiller DJ. Evidence that alteration in renal metabolism and lipid peroxidation may contribute to nephrotoxicity. Transplantation 1990; 50: 487.
48. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89: 10.
49. Trifillis AL, Kahng MW. Effect of cyclosporin A on cultured human kidney cells. Transplant Proc 1988; 3(3): 717.
50. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620.
51. Beckman JS. Ischemic injury mediator. Nature 1990; 345: 27.
52. Laragh JH, Pickering TG. Essential hypertension, in Brenner BM, Rector FC (ed.), The kidney. Philadelphia: Saunders, 1991; 1909.
53. Mihatsch MJ, Thiel G, Spichtin HP, et al. Morphological findings in kidney transplants after treatment with cyclosporine. Transplant Proc 1983; XV(suppl 1): 2821.
54. Chan BBK, Kern JA, Flanagan TL, Kron IL, Tribble CG. Effects of in vivo cyclosporine administration on endothelium-dependent responses in isolated vascular rings. Circulation 1992; 86: SII-295.